¼¼°èÀÇ N95 ¸¶½ºÅ© ½ÃÀå(2024-2031³â)
Global N95 Mask Market - 2024 - 2031
»óǰÄÚµå : 1560832
¸®¼­Ä¡»ç : DataM Intelligence
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 181 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,350 £Ü 6,069,000
PDF & Excel (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,850 £Ü 6,767,000
PDF & Excel (Multiple User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,850 £Ü 10,953,000
PDF & Excel (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ °³¿ä

N95 ¸¶½ºÅ© ¼¼°è ½ÃÀåÀº 2023³â 26¾ï 5,000¸¸ ´Þ·¯, 2031³â¿¡´Â 52¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2031³â°£ ¿¬Æò±Õ 9.2%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

N95 ¸¶½ºÅ©´Â ¿¡¾î·ÎÁ¹°ú °Ç°­¿¡ ÇØ¸¦ ³¢Ä¡´Â Áõ±â¿Í °¡½ºÀÇ ÈíÀÔÀ» ¹æÁöÇϱâ À§ÇØ °³Àκ¸È£±¸(PPE)·Î »ç¿ëµÇ´Â È£Èí±â ¸¶½ºÅ©ÀÇ ÀÏÁ¾À¸·Î, N95 ¸¶½ºÅ©´Â Äڷγª ¹ÙÀÌ·¯½º, SARS, H1N1°ú °°Àº °ø±â Áß ¹ÙÀÌ·¯½º¿Í °°Àº ¹Ì¼¼ÇÑ °ø±â Áß °¨¿° ¿äÀÎÀÇ ÈíÀÔÀ» ¹æÁöÇÕ´Ï´Ù. À¯·´ Ç¥ÁØ¿¡ µû¸£¸é ¿©°úÀ²Àº 95% ÀÌ»ó, ³»ºÎ ´©ÃâÀº 8% ÀÌÇÏ ¿©¾ßÇÕ´Ï´Ù.

N95 ¸¶½ºÅ©´Â Äڷγª ¹ÙÀÌ·¯½º ¹æÁö¿ë ¸¶½ºÅ© Áß °¡Àå ÀϹÝÀûÀÌ°í °¡Àå ¸¹ÀÌ ÆÈ¸®´Â È£Èí±â ¸¶½ºÅ©·Î °Ç¼³, ³ó¾÷, ÀÇ·á, ±Ý¼Ó ¹× ±¤¾÷ µî ´Ù¾çÇÑ »ê¾÷¿¡¼­ »ç¿ëµÇ¾î ÀαⰡ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, N95ÀÇ NÀº "Non-Oil"ÀÇ ¾àÀÚ·Î ±â¸§±â°¡ ¾ø´Â ÀÛ¾÷ ȯ°æ¿¡¼­µµ »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â °ÍÀ» ³ªÅ¸³À´Ï´Ù. 3¹ÌÅ©·Ð ¸¶½ºÅ©´Â ¸ÕÁö, ¹Ì½ºÆ®, Èâ°ú °°Àº ¿À¿°¹°ÁúÀ» °É·¯³¾ ¼ö ÀÖÀ¸¸ç, 95´Â 95%ÀÇ È¿À²À» ³ªÅ¸³À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÃËÁø¿äÀÎ

°¨¿°º´ ¹× È£Èí±â Áúȯ Áõ°¡

°¨¿°º´°ú È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù. °áÇÙ, ¹éÀÏÇØ, Á¶·ù µ¶°¨, ¾Æµ¥³ë ¹ÙÀÌ·¯½º °¨¿°°ú °°Àº Àü¿°º´Àº N95 ¸¶½ºÅ©¸¦ Âø¿ëÇÏ¸é ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2022³â¿¡´Â ÃÑ 130¸¸ ¸íÀÌ °áÇÙÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °áÇÙÀº Äڷγª19¿¡ ÀÌ¾î µÎ ¹øÂ°·Î ¸¹Àº °¨¿°¼º Áúȯ(HIV¿Í AIDS¸¦ ´É°¡)À̸ç, 2022³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 1,060¸¸ ¸íÀÌ °áÇÙ¿¡ °É¸± °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ±× Áß ³²¼º 580¸¸ ¸í, ¿©¼º 350¸¸ ¸í, ¾î¸°ÀÌ 130¸¸ ¸íÀÌ °áÇÙ¿¡ °É¸± °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. °áÇÙÀº ¸ðµç ±¹°¡¿Í ¿¬·É´ë¿¡ Á¸ÀçÇÕ´Ï´Ù. °áÇÙÀº Ä¡·áÇÒ ¼ö ÀÖ°í ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù.

cdc.gov¿¡ µû¸£¸é ÀåÆ¼Çª½º´Â Àü ¼¼°èÀûÀ¸·Î ¸Å³â 1,100¸¸-2,100¸¸ °Ç, ÆÄ¶óƼǪ½º´Â 5¹é¸¸ °ÇÀÌ ¹ß»ýÇϸç, 13¸¸5,000-23¸¸ ¸íÀÌ »ç¸ÁÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ì±¹ ³» ÀåÆ¼Çª½º ȯÀÚÀÇ ¾à 85%, ÆÄ¶óƼǪ½º ȯÀÚÀÇ 92%´Â ÇØ¿Ü ¿©ÇàÀÚ¿¡¼­ ¹ß»ýÇϸç, ´ëºÎºÐ ³²¾Æ½Ã¾Æ(ÁÖ·Î ¹æ±Û¶óµ¥½Ã, Àεµ, ÆÄŰ½ºÅº)¿¡¼­ ±Í±¹ÇÑ »ç¶÷µéÀÔ´Ï´Ù.

¾ïÁ¦¿äÀÎ

°æÀï, ½ÃÀå Æ÷È­, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ¿øÀÚÀç °ø±Þ¸Á È¥¶õ µîÀÇ ¿äÀÎÀÌ ½ÃÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼°è N95 ¸¶½ºÅ© ½ÃÀåÀº Á¦Ç°, ¿ëµµ, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

N95 ¸¶½ºÅ© ¼¼°è ½ÃÀå Á¡À¯À²Àº Ç¥ÁØ N95 È£Èíº¸È£±¸ ºÎ¹®ÀÌ ¾à 34.6%¸¦ Â÷ÁöÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Ç¥ÁØ N95 È£Èí±â ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®¿¡¼­´Â Á¤ºÎ ±ÔÁ¦ÀÇ °³¹ß°ú ¼ö¿ä Áõ°¡°¡ ÀÌ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç¥ÁØ N95 È£Èíº¸È£±¸´Â ¾ó±¼¿¡ ¹ÐÂøµÇ¾î °ø±â ÁßÀÇ ÀÔÀÚ¸¦ È¿À²ÀûÀ¸·Î °É·¯³»´Â È£Èí±â º¸È£ ÀåÄ¡ÀÔ´Ï´Ù. È£Èíº¸È£±¸ÀÇ °¡ÀåÀÚ¸®´Â ÄÚ¿Í ÀÔ ÁÖÀ§¸¦ ¹ÐÆóÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. Ç¥ÁØ N95 È£Èíº¸È£±¸´Â Âø¿ëÀÚ°¡ °ø±â ÁßÀÇ ¹Ì¸³ÀÚ À§Çè¿¡ ´ëÇÑ ³ëÃâÀ» ÁÙÀÏ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¹Ì±¹ ±¹¸³»ê¾÷¾ÈÀüº¸°Ç¿¬±¸¿ø(NIOSH)ÀÌ ¿©°ú È¿À²°ú °°Àº ¹°¸®Àû, ¼º´ÉÀû Ư¼º¿¡ µû¶ó È£Èíº¸È£±¸¸¦ ½ÃÇèÇϰí ÀÎÁõÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº° ½ÃÀå ºÐ¼®

ºÏ¹Ì, N95 ¸¶½ºÅ© ¼¼°è ½ÃÀå Á¡À¯À²ÀÇ ¾à 42.6% Â÷Áö

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â °¨¿°¼º Áúȯ°ú È£Èí±â ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿Í »ç¶÷µéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, Center for Infectious Disease Research and Policy°¡ 2024³â 3¿ù¿¡ ¹ßÇ¥ÇÑ ±â»ç¿¡ µû¸£¸é ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)ÀÇ »õ·Î¿î µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹ÀÇ °áÇ٠ȯÀÚ ¼ö´Â 2023³â¿¡ Áõ°¡ÇÏ¿© 3³â ¿¬¼Ó Áõ°¡Çß´Ù°í ÇÕ´Ï´Ù. ¹ßÇ¥µÈ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡¼­ º¸°íµÈ °áÇ٠ȯÀÚ ¼ö´Â 9,615¸íÀ¸·Î 2022³âº¸´Ù 16% Áõ°¡ÇØ 2013³â ÀÌÈÄ °¡Àå ¸¹Àº °áÇ٠ȯÀÚ°¡ º¸°íµÆ½À´Ï´Ù. °áÇÙ ¹ßº´·üÀº 10¸¸ ¸í´ç 2.9¸íÀ¸·Î 2022³â ´ëºñ 15% Áõ°¡Çß½À´Ï´Ù. °áÇÙ ¹ßº´·üÀº ¸ðµç ¿¬·É´ë¿¡¼­ Áõ°¡ÇßÀ¸¸ç, 5¼¼¿¡¼­ 14¼¼ »çÀÌÀÇ ¾î¸°ÀÌ¿¡¼­ °¡Àå Å« Áõ°¡¸¦ º¸¿´½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå »ê¾÷ ºÐ¼®

Á¦6Àå Á¦Ç°º°

Á¦7Àå ¿ëµµº°

Á¦8Àå À¯Çüº°

Á¦9Àå ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå Áö¿ªº°

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ±â¾÷ °³¿ä

Á¦13Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Report Overview

The Global N95 Mask Market reached US$ 2.65 billion in 2023 and is expected to reach US$ 5.27 billion by 2031, growing at a CAGR of 9.2% during the forecast period 2024-2031.

An N95 is a type of respirator mask used as personal protective equipment for the prevention of inhaling aerosols as well as vapors or gases that are health hazards. N95 mask also protects against inhaling micro airborne infectious agents such as airborne viruses including coronavirus, SARS, H1N1, etc. According to the European standard, it should have a minimum of 95% filtration and a maximum of 8% leakage to the inside.

N95 masks are gaining popularity as it is considered the most common and best-selling type of respirator mask, for protection against the coronavirus, it is also used in versatile industries such as construction, agriculture, healthcare, metals & mining, and others. In N95, the N stands for "Non-Oil" and indicates that the mask can be used in a work environment without oil-based particulates, the 95 indicates that the mask has a 95% efficiency rate. The 3-micron mask filters out contaminants like specks of dust, mists, and fumes.

Market Dynamics: Drivers

Increasing prevalence of infectious and respiratory diseases

The rising prevalence of infectious and respiratory diseases propels the market growth. Infectious diseases such as tuberculosis, pertussis, avian influenza, and adenovirus infections can be prevented by wearing N95 masks. For instance, according to WHO, a total of 1.3 million people died from TB in 2022. Worldwide, TB is the second leading infectious killer after COVID-19 (above HIV and AIDS). In 2022, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide, including 5.8 million men, 3.5 million women and 1.3 million children. TB is present in all countries and age groups. TB is curable and preventable.

According to cdc.gov, an estimated 11-21 million cases of typhoid fever and 5 million cases of paratyphoid fever occurs worldwide each year, causing an estimated 135,000-230,000 deaths. Approximately 85% of typhoid fever and 92% of paratyphoid fever cases in the United States occur among international travelers; most are travelers returning from South Asia, primarily Bangladesh, India, and Pakistan.

Restraints

Factors such as competition and market saturation, stringent regulatory requirements, supplychain disruptions regarding raw materials are expected to hamper the market.

Market Segment Analysis

The global N95 mask market is segmented based on product, usage, type, end-user, and region.

The segment standard N95 respirator accounted for approximately 34.6% of the global N95 mask market share

The standard N95 respirator segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and increasing demand would drive this market.

A standard N95 respirator is a respiratory protective device that fits closely to the face and filters airborne particles efficiently. The edges of the respirator are designed to seal around the nose and mouth. Standard N95 respirators are designed to help reduce the wearer's exposure to airborne particulate hazards. In the U.S., respirators are tested and certified by the U.S. National Institute of Occupational Safety and Health (NIOSH). NIOSH tests and certifies respirators based on their physical and performance characteristics, including filtration efficiency.

Market Geographical Analysis

North America accounted for approximately 42.6% of the global N95 mask market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of infectious and respiratory diseases, and growing awareness among people, in this region, help to propel the market.

For instance, according to an article posted by Center for Infectious Disease Research and Policy in March 2024, the number of tuberculosis (TB) cases in the United States climbed in 2023, the third straight year of increases, according to new data from the Centers for Disease Control and Prevention (CDC). The data published showed that 9,615 TB cases were reported in the United States in 2023, a 16% increase from 2022 and the highest number reported since 2013. The TB incidence rate of 2.9 cases per 100,000 persons represented a 15% increase from 2022. TB incidence increased in every age group, with the largest increase seen in children ages 5 to 14 years.

As in previous years, most reported TB cases in 2023 (76%) occurred in non-US-born residents. But case counts rose among both US-born and non-US-born residents, who saw increases of 9% and 18%, respectively. Among US-born persons with TB, 33% were Black, 27% Hispanic, 26% White, 6% Asian, 5% American Indian or Native Alaskan, and 3% Native Hawaiian or other Pacific Islander.

Market Segmentation

By Product

With Exhalation Valve

Without Exhalation Valve

By Usage

Reusable

Disposable

By Type

Standard N95 Respirator

Surgical N95 Respirator

By End-User

Hospitals

Mining Industries

Construction Firms

Oil & Gas Industries

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global N95 mask market include Shawmut Corporation, 3M, Honeywell, Ambu A/S, Moldex-Metric Inc., Alpha Pro Tech, Ohlone Press LLC, Teleflex, Kimberly-Clark Corporation, and The Gerson Company among others.

Key Developments

In August 2022, Optrel, a leading manufacturer of respiratory protection, launched the P Air Clear, the world's first NIOSH-approved N95 respirator with a transparent window. Swiss-made with the highest quality material for comfort and function, the P Air Clear features a transparent window, a latex-free head harness, and an adjustable nose clip.

In April 2022, RB Sigma announced that its domestically manufactured N95 Filtering Facepiece Respirator was approved by the National Institute for Occupational Safety and Health (NIOSH).

Why Purchase the Report?

To visualize the global N95 mask market segmentation based on product, usage, type, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global N95 mask market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global N95 mask market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

2. Definition and Overview

3. Executive Summary

4. Dynamics

5. Industry Analysis

6. By Product

7. By Usage

8. By Type

9. By End-User

10. By Region

11. Competitive Landscape

12. Company Profiles

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â